Suchergebnisse - "Lappegård, Knut Tore"

PubPharm (108)

31

Health-related quality of life on tele-monitoring for users with pacemakers 6 months after implant: the NORDLAND study, a randomized trial

enthalten in: BMC geriatrics | 2018

von Lopez-Villegas, A. | Catalan-Matamoros, D. | Lopez-Liria, R. | +3

32

CVD Risk Stratification in the PCSK9 Era : Is There a Role for LDL Subfractions?

enthalten in: Diseases (Basel, Switzerland) | 2018

von Kjellmo, C. | Hovland, A. | Lappegård, K.

33

Granulocyte and monocyte CD11b expression during plasma separation is dependent on complement factor 5 (C5) - an ex vivo study with blood from a C5-deficient individual

enthalten in: APMIS : acta pathologica, microbiologica, et immunologica Scandinavica | 2018

von Hardersen, R. | Enebakk, T. | Christiansen, D. | +5

34

Lipoprotein apheresis affects lipoprotein particle subclasses more efficiently compared to the PCSK9 inhibitor evolocumab, a pilot study

enthalten in: Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis | 2018

von Lappegård, K. | Kjellmo, C. | Ljunggren, S. | +5

35

Bariatric surgery improves lipoprotein profile in morbidly obese patients by reducing LDL cholesterol, apoB, and SAA/PON1 ratio, increasing HDL cholesterol, but has no effect on cholesterol efflux capacity

enthalten in: Journal of clinical lipidology | 2018

von Kjellmo, C. | Karlsson, H. | Nestvold, T. | +6

36

Bariatric surgery reduces fasting total fatty acids and increases n-3 polyunsaturated fatty acids in morbidly obese individuals

enthalten in: Scandinavian journal of clinical and laboratory investigation | 2017

von Hovland, A. | Nestvold, T. | Bohov, P. | +6

37

Recurrence and Severe Worsening of Hepatotoxicity After Reintroduction of Atorvastatin in Combination With Ezetimibe

enthalten in: Clinical medicine insights. Case reports | 2017

von Bergland Ellingsen, S. | Nordmo, E. | Lappegård, K.

38

LDL apheresis activates the complement system and the cytokine network, whereas PCSK9 inhibition with evolocumab induces no inflammatory response

enthalten in: Journal of clinical lipidology | 2016

von Lappegård, K. | Enebakk, T. | Thunhaug, H. | +3

39

Transition from LDL apheresis to evolocumab in heterozygous FH is equally effective in lowering LDL, without lowering HDL cholesterol

enthalten in: Atherosclerosis | 2016

von Lappegård, K. | Enebakk, T. | Thunhaug, H. | +1

40

Major Increase in Microbiota-Dependent Proatherogenic Metabolite TMAO One Year After Bariatric Surgery

enthalten in: Metabolic syndrome and related disorders | 2016

von Trøseid, M. | Hov, J. | Nestvold, T. | +4

CommentIn: Metab Syndr Relat Disord. 2016 May;14(4):195-6. - PMID 26958935